NVS250117P82500
- 2.35
- 0.000.00%
Novartis AG Newsroom
Top Gap Ups and Downs on Monday: TSM, HMC, GFI and More
Why Is Novartis AG (NVS) Among the Best European Dividend Stocks To Buy Now?
RAPT Rockets 180% on Licensing Deal, $150M Private Placement
Novartis Says 330 Jobs Hit as It Closes MorphoSys Sites
European Stocks That Trade Cheaper Than U.S. Peers
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Sanofi: Kress Was the CEO of MorphoSys From 2019 Until It Was Acquired by Novartis in 2024
Market Chatter: Novartis to Close MorphoSys Sites, Affecting 330 Jobs
Novartis AG (NOVN) Gets a Sell From Barclays
The prospects of European Medical Care stocks are complex, with USA policies and new drug trial results being the key factors.
After falling from a high position in the last few months of 2024, European Medical Care stocks face the risks of US politics and the results of high-risk new drug trials in the new year.
Top Gap Ups and Downs on Wednesday: CI, IBN, EA and More
Express News | CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
Express News | CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
BioAge Stock Advances 14% On Novartis Research Collaboration
BioAge Labs Says It Is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Alcon a Top Pick for 2025 at Needham on Upcoming Product Launches
NVS Vs. LLY: Which Stock Should Value Investors Buy Now?
Deutsche Bank Remains a Hold on Novartis AG (NOVN)
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report